Hyperlipidemia Drugs Market Report

Hyperlipidemia Drugs Market Analysis Report by Drug Class (Statins, PCSK9 Inhibitors, Bile Acid Sequestrants, Cholesterol Absorption Inhibitors, Fibric Acid Derivatives, Combination), and Segment Forecasts, 2016 - 2022

  • Report ID: GVR-2-68038-525-0
  • Number of Pages: 98
  • Format: Electronic (PDF)
  • Historical Range: 2014 - 2016
  • Industry: Healthcare

Table of Contents

Chapter 1 Research Methodology
                 1.1 Information procurement
                 1.2 Information or Data Analysis
                     1.2.1 Market formulation & validation
Chapter 2 Executive Summary
                 2.1 Market Snapshot
Chapter 3 Disease Primer and Epidemiology
                 3.1 Disease Primer
                     3.1.1 Types:
                         3.1.1.1 Type I
                         3.1.1.2 Type II
                         3.1.1.3 Type III
                         3.1.1.4 Type IV
                         3.1.1.5 Type V
                     3.1.2 Complications
                 3.2 Epidemiology by Indications
                 3.3 Current Prevalence for Seven Major Markets (U.S., Japan, & EU5)
                 3.4 Current Incidence for Seven Major Markets (U.S., Japan, & EU5)
                 3.5 Forecast Prevalence and Incidence for Seven Major Markets (U.S., Japan, & EU5)
Chapter 4 Global Hyperlipidemia Drugs Market Overview
                 4.1 Introduction and Market Overview
                     4.1.1 Segmentation by region
                         4.1.1.1 U.S.
                         4.1.1.2 U.K.
                         4.1.1.3 Germany
                         4.1.1.4 Spain
                         4.1.1.5 France
                         4.1.1.6 Italy
                         4.1.1.7 Japan
                     4.1.2 Segmentation by drug class
                         4.1.2.1 Statins
                         4.1.2.2 Bile acid sequestrants
                         4.1.2.3 Cholesterol absorption inhibitors
                         4.1.2.4 Fibric acid derivatives
                         4.1.2.5 PCSK9 inhibitors
                         4.1.2.6 Combination
                         4.1.2.7 Miscellaneous antihyperlipidemic agents
                     4.1.3 Market size & forecast
                     4.1.4 Sales performance
                     4.1.5 Market share distribution
                     4.1.6 Market dynamics among leading brands
                 4.2 Patent Expiry Schedule
                 4.3 Drivers and Challenges
                 4.4 M&A, Deal Landscape (2013 - 2017 YTD)
                 4.5 Pricing and Reimbursement
                 4.6 SWOT analysis
Chapter 5 Hyperlipidemia Drugs Market: Pipeline Intelligence
                 5.1 Pipeline Landscape
                     5.1.1 Leading drugs in development
                     5.1.2 Key R&D trends
                         5.1.2.1 PCSK9 inhibition
                         5.1.2.2 Antisense therapy
                         5.1.2.3 Gene silencing
                         5.1.2.4 Omega - 3 fatty acid
                         5.1.2.5 ATP - citrate lyase
                         5.1.2.6 DGAT2 inhibitor
                         5.1.2.7 ANGPTL - 3 antibody
                 5.2 Promising Drugs in Pipeline
                     5.2.1 Late stage pipeline and sales forecast
                     5.2.2 Profile of disruptive drugs
                         5.2.2.1 Repatha
                         5.2.2.2 Praluent
                         5.2.2.3 Bempedoic acid
                         5.2.2.4 K - 877/Pemafibrate
Chapter 6 Company Profiles
                 6.1 AstraZeneca
                     6.1.1 Company overview
                     6.1.2 Current product portfolio
                     6.1.3 Product sales forecast through 2022
                     6.1.4 Key facts
                         6.1.4.1 Crestor
                         6.1.4.2 Epanova
                     6.1.5 Company - Key news flow
                     6.1.6 Pipeline view
                     6.1.7 Pipeline forecast
                     6.1.8 Catalysts and event calendar
                     6.1.9 SWOT analysis
                 6.2 Merck
                     6.2.1 Company overview
                     6.2.2 Current product portfolio
                     6.2.3 Product sales forecast through 2022
                     6.2.4 Key facts
                         6.2.4.1 Zetia
                         6.2.4.2 Zocor
                         6.2.4.3 Vytorin
                     6.2.5 Company - Key news flow
                     6.2.6 Catalysts and event calendar
                     6.2.7 SWOT analysis
                 6.3 Pfizer
                     6.3.1 Company overview
                     6.3.2 Current product portfolio
                     6.3.3 Product sales forecast through 2022
                     6.3.4 Key facts
                         6.3.4.1 Lipitor
                         6.3.4.2 Caduet
                     6.3.5 Company - Key news flow
                     6.3.6 Pipeline view
                     6.3.7 Pipeline forecast
                     6.3.8 Catalysts and event calendar
                     6.3.9 SWOT analysis
                 6.4 Daiichi Sankyo
                     6.4.1 Company overview
                     6.4.2 Current product portfolio
                     6.4.3 Product sales forecast through 2022
                     6.4.4 Key facts
                         6.4.4.1 Welchol
                         6.4.4.2 Mevalotin
                     6.4.5 SWOT analysis
                 6.5 Amgen
                     6.5.1 Company overview
                     6.5.2 Current product portfolio
                     6.5.3 Product sales forecast through 2022
                     6.5.4 Key facts
                         6.5.4.1 Repatha
                     6.5.5 Company - Key news flow
                     6.5.6 Pipeline view
                     6.5.7 Pipeline forecast
                     6.5.8 SWOT analysis
                 6.6 Sanofi
                     6.6.1 Company overview
                     6.6.2 Current product portfolio
                     6.6.3 Product sales forecast through 2022
                     6.6.4 Key facts
                         6.6.4.1 Praluent
                     6.6.5 Company - Key news flow
                     6.6.6 Pipeline view
                     6.6.7 Pipeline forecast
                     6.6.8 Catalysts and event calendar
                     6.6.9 SWOT analysis
Chapter 7 Market Outlook
                 7.1 What the future holds
                 7.2 Winners and Losers
                 7.3 Emerging Companies
                 7.4 The Road Ahead


List of Tables

TABLE 1 Current hyperlipidemia prevalence for seven major markets - 2016
TABLE 2 Current hyperlipidemia incidence for seven major markets - 2016
TABLE 3 Forecast hyperlipidemia prevalence for seven major markets 2016 - 2022
TABLE 4 Forecast hyperlipidemia incidence for seven major markets 2016 - 2022
TABLE 5 Statin classification by intensity
TABLE 6 Hyperlipidemia drugs market size and forecast (in US million)
TABLE 7 Geographic sales performance by seven major markets (in US million)
TABLE 8 Hyperlipidemia drugs market by drug class (in US million)
TABLE 9 Forecast sales of leading brands (in US million)
TABLE 10 Global hyperlipidemia pipeline forecast
TABLE 11 Global hyperlipidemia pipeline sales forecast (in US million)
TABLE 12 Hyperlipidemia sales forecast by company (in US million)
TABLE 13 Hyperlipidemia drugs market share by company (in US million)
TABLE 14 Hyperlipidemia patent expiry schedule
TABLE 15 M&A, deal landscape
TABLE 16 Leading antihyperlipidemic drugs in pipeline
TABLE 17 Late-stage pipeline and sales forecast
TABLE 18 Profile of disruptive drug: Repatha
TABLE 19 Profile of disruptive drug: Praluent
TABLE 20 Profile of disruptive drug: Bempedoic Acid
TABLE 21 Profile of disruptive drug: Pemafibrate
TABLE 22 Product portfolio: Crestor
TABLE 23 Product portfolio: Epanova
TABLE 24 Crestor sales forecast through 2022
TABLE 25 AstraZeneca pipeline view
TABLE 26 AstraZeneca catalysts and event calendar
TABLE 27 Product portfolio: Zetia
TABLE 28 Product portfolio: Zocor
TABLE 29 Product portfolio: Vytorin
TABLE 30 Zetia sales forecast through 2022
TABLE 31 Zocor sales forecast through 2022
TABLE 32 Vytorin sales forecast through 2022
TABLE 33 Merck catalysts and event calendar
TABLE 34 Product portfolio: Lipitor
TABLE 35 Product portfolio: Caduet
TABLE 36 Lipitor sales forecast through 2022
TABLE 37 Caduet sales forecast through 2022
TABLE 38 Pfizer pipeline view
TABLE 39 Pfizer catalysts and event calendar
TABLE 40 Product portfolio: Welchol
TABLE 41 Product portfolio: Mevalotin
TABLE 42 Welchol sales forecast through 2022
TABLE 43 Product portfolio: Repatha
TABLE 44 Repatha sales forecast through 2022
TABLE 45 Amgen pipeline view
TABLE 46 Product portfolio: Praluent
TABLE 47 Praluent sales forecast through 2022
TABLE 48 Sanofi pipeline view
TABLE 49 Sanofi catalysts and event calendar


List of Figures

FIG. 1 Market research process
FIG. 2 Information procurement
FIG. 3 Primary research pattern
FIG. 4 Market research approaches
FIG. 5 Value chain-based sizing & forecasting
FIG. 6 QFD modelling for market share assessment
FIG. 7 Market summary, 2016
FIG. 8 Current prevalence for seven major markets - 2016
FIG. 9 Current incidence for seven major markets - 2016
FIG. 10 Market segmentation & scope
FIG. 11 Geographic sales performance by seven major markets 2016
FIG. 12 Hyperlipidemia drugs market by drug class
FIG. 13 Hyperlipidemia market share by company 2016 - 2022
FIG. 14 Market trends & outlook
FIG. 15 Market driver relevance analysis (Current & future impact)
FIG. 16 Market restraint relevance analysis (Current & future impact)
FIG. 17 SWOT analysis (Hyperlipidemia drugs market)
FIG. 18 SWOT analysis (AstraZeneca)
FIG. 19 SWOT analysis (Merck)
FIG. 20 SWOT analysis (Pfizer)
FIG. 21 SWOT analysis (Daiichi Sankyo)
FIG. 22 SWOT analysis (Amgen)
FIG. 23 SWOT analysis (Sanofi)

What questions do you have? Get quick response from our industry experts. Request a Free Consultation
pdf

GET A FREE SAMPLE

bck

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

cog

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.

great place to work icon